STAT6 and Huntington disease: Examples include the exoASOTM platform from Codiak BioSciences, which targets transcriptional regulators like STAT6 in tumor-associated macrophages [116], and Evox Therapeutics’ genome-editing exosomes, developed for disorders like Spinocerebellar Ataxia 2 and Huntington’s disease [111].